Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.
2,038 results
  • Optogenetic and pharmacological interventions link hypocretin neurons to impulsivity in mice. [Journal Article]
    Commun Biol. 2023 Jan 19; 6(1):74.Tyree SM, Jennings KJ, … de Lecea L
  • Neurons in the lateral hypothalamus expressing the neuropeptide Hypocretin, also known as orexin, are known critical modulators of arousal stability. However, their role in the different components of the arousal construct such as attention and decision making is poorly understood. Here we study Hypocretin neuronal circuit dynamics during stop action impulsivity in a Go/NoGo task in mice. We show…
  • Reduced attentional lapses in male rats following a combination treatment of low-dose D-serine and atomoxetine. [Journal Article]
    J Psychopharmacol. 2023 Jan 17 [Online ahead of print]Redding ZV, Sabol KE
  • CONCLUSIONS: IT devmode is thought to reflect attentional lapses; therefore, D-serine's effects on IT devmode suggest that NMDA receptors are involved in the preparatory deployment of attention. Greater effects following a combination of D-serine and atomoxetine suggest that preparatory attention can be facilitated by targeting glutamatergic and noradrenergic systems simultaneously. These results could inform the development of improved treatments for individuals with ADHD who experience abnormally high attentional lapses.
  • Personalizing atomoxetine dosing in children with ADHD: what can we learn from current supporting evidence. [Review]
    Eur J Clin Pharmacol. 2023 Jan 16 [Online ahead of print]Fu D, Guo HL, … Chen F
  • CONCLUSIONS: Personalizing atomoxetine dosage may be even more complex than anticipated thus far, but elucidating the best way to tailor the non-stimulant to a patient's individual need will be achieved by combining two strategies: detailed research in linking the pharmacokinetics and pharmacodynamics in pediatric patients, and better understanding in nature and causes of ADHD, as well as environmental stressors.
  • Drugs and Lactation Database (LactMed): Atomoxetine [BOOK]
    Drugs and Lactation Database (LactMed). National Library of Medicine (US): Bethesda (MD)BOOK
  • There is no published experience with atomoxetine during breastfeeding, although reports from the manufacturer found no serious adverse effects in two breastfed infants. An alternate drug may be preferred, especially while nursing a newborn or preterm infant.
  • One Month Dosing of Atomoxetine plus Oxybutynin in Obstructive Sleep Apnea: A Randomized, Placebo-controlled Trial. [Journal Article]
    Ann Am Thorac Soc. 2022 Dec 20 [Online ahead of print]Aishah A, Loffler KA, … Eckert DJ
  • CONCLUSIONS: 1 month of nightly noradrenergic and anti-muscarinic combination therapy was generally well-tolerated with a side effect profile consistent with each agent alone and was associated with an ~50% reduction from baseline in a key OSA severity metric, the hypoxic burden with the highest dose combination. These findings highlight the potential to target noradrenergic and anti-muscarinic mechanisms for OSA pharmacotherapy development.
  • Atomoxetine for suppression of vasovagal syncope. [Journal Article]
    Clin Auton Res. 2022 Nov 19 [Online ahead of print]Sheldon RS, Seifer C, … Raj SR
  • CONCLUSIONS: In this case series, atomoxetine was a promising oral agent for the prevention of vasovagal syncope. The Poisson distribution permits individual patient-level assessment of improvement and detects insufficient follow-up despite apparent improvement.
  • Novel non-stimulants rescue hyperactive phenotype in an adgrl3.1 mutant zebrafish model of ADHD. [Journal Article]
    Neuropsychopharmacology. 2022 Nov 18 [Online ahead of print]Sveinsdóttir HS, Christensen C, … Karlsson KÆ
  • ADHD is a highly prevalent neurodevelopmental disorder. The first-line therapeutic for ADHD, methylphenidate, can cause serious side effects including weight loss, insomnia, and hypertension. Therefore, the development of non-stimulant-based therapeutics has been prioritized. However, many of these also cause other effects, most notably somnolence. Here, we have used a uniquely powerful genetic m…
  • Chondral/Desmal Osteogenesis in 3D Spheroids Sensitized by Psychostimulants. [Journal Article]
    J Clin Med. 2022 Oct 21; 11(20)Wagener N, Lehmann W, … Di Fazio P
  • Attention deficit hyperactivity disorder (ADHD) affects 6.4 million children in the United States of America. Children and adolescents, the main consumers of ADHD medication, are in the bone growth phase, which extends over a period of up to two decades. Thus, impaired proliferation and maturation of chondrocytes and osteoblasts can result in impaired bone formation. The aim of this study is to i…
  • Therapeutic Approaches for ADHD by Developmental Stage and Clinical Presentation. [Review]
    Int J Environ Res Public Health. 2022 10 08; 19(19)Galvez-Contreras AY, Vargas-de la Cruz I, … Gonzalez-Perez O
  • Attention Deficit Hyperactivity Disorder is a neurodevelopmental disorder with three presentations: inattentive, hyperactive/impulsive and combined. These may represent an independent disease entity. Therefore, the therapeutic approach must be focused on their neurobiological, psychological and social characteristics. To date, there is no comprehensive analysis of the efficacy of different treatm…
New Search Next